ZA200602888B - Compounds and methods for treating dyslipidemia - Google Patents

Compounds and methods for treating dyslipidemia Download PDF

Info

Publication number
ZA200602888B
ZA200602888B ZA200602888A ZA200602888A ZA200602888B ZA 200602888 B ZA200602888 B ZA 200602888B ZA 200602888 A ZA200602888 A ZA 200602888A ZA 200602888 A ZA200602888 A ZA 200602888A ZA 200602888 B ZA200602888 B ZA 200602888B
Authority
ZA
South Africa
Prior art keywords
alkyl
compound
formula
cycloalkyl
composition
Prior art date
Application number
ZA200602888A
Other languages
English (en)
Inventor
Cao Guoqing
Fernandez Maria Carmen
Gernert Douglas Linn
Herr Robert Jason
Martin De La Nava Eva Maria
Mayhugh Daniel Ray
Escribano Ana Maria
Fields Todd
Cioffi Christoper Lawrence
Mantlo Nathan Bryan
Mateo Herranz Ana Isabel
Wang Xiaodong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200602888B publication Critical patent/ZA200602888B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200602888A 2003-10-08 2006-04-07 Compounds and methods for treating dyslipidemia ZA200602888B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50973603P 2003-10-08 2003-10-08

Publications (1)

Publication Number Publication Date
ZA200602888B true ZA200602888B (en) 2007-11-28

Family

ID=34465112

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200602888A ZA200602888B (en) 2003-10-08 2006-04-07 Compounds and methods for treating dyslipidemia

Country Status (25)

Country Link
US (1) US7749992B2 (ja)
EP (2) EP1670768B1 (ja)
JP (1) JP4773969B2 (ja)
KR (1) KR20060085675A (ja)
CN (1) CN1863778A (ja)
AT (1) ATE442358T1 (ja)
AU (1) AU2004282101A1 (ja)
BR (1) BRPI0414186A (ja)
CA (1) CA2537942A1 (ja)
CY (1) CY1110537T1 (ja)
DE (1) DE602004023100D1 (ja)
DK (1) DK1670768T3 (ja)
EA (1) EA200600737A1 (ja)
EC (1) ECSP066484A (ja)
ES (1) ES2332051T3 (ja)
HR (1) HRP20090581T1 (ja)
IL (1) IL173819A0 (ja)
MA (1) MA28268A1 (ja)
MX (1) MXPA06003927A (ja)
NO (1) NO20062074L (ja)
PL (1) PL1670768T3 (ja)
PT (1) PT1670768E (ja)
SI (1) SI1670768T1 (ja)
WO (1) WO2005037796A1 (ja)
ZA (1) ZA200602888B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735320B1 (en) * 2004-03-26 2009-06-17 Eli Lilly And Company Compounds and methods for treating dyslipidemia
KR20070041452A (ko) 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) * 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
CN103833636B (zh) * 2014-03-31 2015-09-02 武汉武药制药有限公司 一种莫扎伐普坦中间体的合成方法
MA42527A (fr) * 2015-07-31 2021-04-07 Arena Pharm Inc Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
CN110291383B (zh) * 2017-02-23 2021-12-28 株式会社Ihi Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法
WO2020084492A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2021256166B2 (en) 2020-04-15 2024-05-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
TW270927B (ja) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
CN1144487A (zh) * 1994-03-24 1997-03-05 默里尔药物公司 降低胆固醇、抗动脉粥样硬化和降低甘油三酯的巯基乙酰胺衍生物
PT1221440E (pt) * 1994-06-15 2007-07-20 Otsuka Pharma Co Ltd Derivados benzo-heterocíclicos úteis como moduladores da vasopressina ou oxitocina
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
JPH09214746A (ja) 1996-02-02 1997-08-15 Ricoh Co Ltd 画像出力システム及び画像形成装置
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Fo−5637a物質及びb物質並びにそれらの製造法
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6664522B2 (en) * 2000-03-30 2003-12-16 Homer L. Spencer Method and apparatus for sealing multiple casings for oil and gas wells
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1383734B1 (en) * 2001-04-30 2006-02-01 Pfizer Products Inc. Compounds useful as intermediates for 4-aminoquinoline derivatives
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2004003054A1 (en) 2002-07-01 2004-01-08 Surface Specialties, S.A. Water-thinnable polymer precursors, their preparation and use
EP1533292B1 (en) 2002-08-30 2007-02-14 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
EP1601655A2 (en) 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
MXPA06003499A (es) 2003-09-30 2006-06-08 Pfizer Prod Inc Inhibidores de proteina de transferencia de esteres de colestrerilo y sus metabolitos.
EP1735320B1 (en) * 2004-03-26 2009-06-17 Eli Lilly And Company Compounds and methods for treating dyslipidemia
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
DE602004023100D1 (de) 2009-10-22
US7749992B2 (en) 2010-07-06
US20070254869A1 (en) 2007-11-01
JP4773969B2 (ja) 2011-09-14
EP1670768A1 (en) 2006-06-21
JP2007508301A (ja) 2007-04-05
MA28268A1 (fr) 2006-11-01
MXPA06003927A (es) 2008-02-07
DK1670768T3 (da) 2009-11-09
ATE442358T1 (de) 2009-09-15
KR20060085675A (ko) 2006-07-27
CN1863778A (zh) 2006-11-15
EA200600737A1 (ru) 2006-10-27
PL1670768T3 (pl) 2010-01-29
ES2332051T3 (es) 2010-01-25
PT1670768E (pt) 2009-11-20
ECSP066484A (es) 2006-10-10
HRP20090581T1 (hr) 2009-12-31
EP2098512A1 (en) 2009-09-09
CA2537942A1 (en) 2005-04-28
EP1670768B1 (en) 2009-09-09
AU2004282101A1 (en) 2005-04-28
CY1110537T1 (el) 2015-04-29
IL173819A0 (en) 2006-07-05
BRPI0414186A (pt) 2006-10-31
NO20062074L (no) 2006-05-08
WO2005037796A1 (en) 2005-04-28
SI1670768T1 (sl) 2010-01-29

Similar Documents

Publication Publication Date Title
ZA200602888B (en) Compounds and methods for treating dyslipidemia
EP2142541B1 (en) Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
TWI791511B (zh) 細胞凋亡誘導劑
EP2896624B1 (en) Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
ES2416711T3 (es) Compuestos espiro sustituidos como inhibidores de la angiogénesis
US6835737B2 (en) Quinoline inhibitors of cGMP phosphodiesterase
AU722480B2 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
PT2125776T (pt) Compostos espiro substituídos como inibidores da angiogénese
WO2006012093A1 (en) Compounds and methods for treating dyslipidemia
KR20070007112A (ko) 이상지혈증 치료를 위한 화합물 및 방법
IL179532A (en) Derivatives of quinazolinone, pharmacological preparations that contain them and their use in the preparation of drugs for the treatment of pain or gastrointestinal disorder
CA2954401C (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
KR20110093948A (ko) 신규 헤테로시클리덴 아세트아미드 유도체
WO2016010869A2 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
JP2010024243A (ja) 緑内障および近視を処置するためのベンゾ[g]キノリン誘導体
CA2332505A1 (en) Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
JP2010095550A (ja) キノリン誘導体
KR100735781B1 (ko) 이소퀴놀린 화합물 및 그의 의약 용도
KR19990076616A (ko) 2,7-치환된 옥타하이드로-피롤로[1,2-에이]피라진 유도체
AU2017350848B2 (en) Compositions and methods for inhibiting kinases
TW593307B (en) Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them
ES2347681T3 (es) Agentes para tratar el herpes genital despues de su aparicion.
SK175298A3 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
US6057334A (en) Benzo[g]quinoline derivatives
AU694513B2 (en) Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants